{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T15:15:46Z","timestamp":1778944546038,"version":"3.51.4"},"reference-count":24,"publisher":"Japanese Society of Internal Medicine","issue":"18","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2025,9,15]]},"DOI":"10.2169\/internalmedicine.4906-24","type":"journal-article","created":{"date-parts":[[2025,3,21]],"date-time":"2025-03-21T18:13:49Z","timestamp":1742580829000},"page":"2747-2754","source":"Crossref","is-referenced-by-count":2,"title":["Plasma Cell-rich Nephritis with a Systemic Polyclonal Lymphoproliferative Disorder, Mimicking Idiopathic Multicentric Castleman Disease, Systemic Lupus Erythematosus, and IgG4-related Disease"],"prefix":"10.2169","volume":"64","author":[{"given":"Yu","family":"Hebisawa","sequence":"first","affiliation":[{"name":"Department of Nephrology, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akihito","family":"Ohta","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryutaro","family":"Sekimoto","sequence":"additional","affiliation":[{"name":"Department of Pathology, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natsuko","family":"Sakurai","sequence":"additional","affiliation":[{"name":"Department of Pathology, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keigo","family":"Setoguchi","sequence":"additional","affiliation":[{"name":"Department of Systemic Immunological Diseases, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1182\/blood.V74.4.1360.1360","volume":"74","author":"K Yoshizaki","year":"1989","unstructured":"1. Yoshizaki K, Matsuda T, Nishimoto N, et al. Pathogenic significance of interleukin-6 (IL-6\/BSF-2) in Castleman's disease. Blood 74: 1360-1367, 1989.","journal-title":"Blood","ISSN":"https:\/\/id.crossref.org\/issn\/0006-4971","issn-type":"print"},{"key":"2","doi-asserted-by":"publisher","unstructured":"2. Fajgenbaum DC, Uldrick TS, Bagg A, et al. International, evidence-based consensus diagnostic criteria for HHV-8-negative\/idiopathic multicentric Castleman disease. Blood 129: 1646-1657, 2017.","DOI":"10.1182\/blood-2016-10-746933"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Gao YH, Lui YT, Zhang MY, et al. Idiopathic multicentric Castleman disease (iMCD)-idiopathic plasmacytic lymphadenopathy: a distinct subtype of iMCD-not otherwise specified with different clinical features and better survival. Br J Haematol 204: 1830-1837, 2024.","DOI":"10.1111\/bjh.19334"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Nishikori A, Nishimura MF, Nishimura Y, et al. Idiopathic plasmacytic lymphadenopathy forms an independent subtype of idiopathic multicentric Castleman disease. Int J Mol Sci 23: 10301, 2022.","DOI":"10.3390\/ijms231810301"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Kojima M, Nakamura N, Tsukamoto N, et al. Clinical implications of idiopathic multicentric Castleman disease among Japanese: a report of 28 cases. Int J Surg Pathol 16: 391-398, 2008.","DOI":"10.1177\/1066896908315812"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Nishimura Y, Nishikori, Sawada H, et al. Idiopathic multicentric Castleman disease with positive antiphospholipid antibody: atypical and undiagnosed autoimmune disease? J Clin Exp Hematop 62: 99-105, 2022.","DOI":"10.3960\/jslrt.21038"},{"key":"7","unstructured":"7. Colvin RB, Chang A, Cornell LD. Diagnostic Pathology Kidney Diseases. 4th ed. Elsevier, Philadelphia, United States, 2023: 163-181."},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Yap DYH, Chan TM. B cell abnormalities in systemic lupus erythematosus and lupus nephritis-role in pathogenesis and effect of immunosuppressive treatments. Int J Mol Sci 20: 6231, 2019.","DOI":"10.3390\/ijms20246231"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Zoshima T, Yamada K, Hara S, et al. Multicentric Castleman disease with tubulointerstitial nephritis mimicking IgG4-related disease: two case reports. Am J Surg Pathol 40: 495-501, 2016.","DOI":"10.1097\/PAS.0000000000000575"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Yamamoto M, Aochi S, Suzuki C, et al. A case with good response to belimumab for lupus nephritis complicated by IgG4-related disease. Lupus 28: 786-789, 2019.","DOI":"10.1177\/0961203319840430"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Arai H, Hayashi H, Ogata S, et al. Progression of immunoglobulin G4-related disease to systematic lupus erythematosus after gastric cancer surgery: A case report. Medicine (Baltimore) 97: e13545, 2018.","DOI":"10.1097\/MD.0000000000013545"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Fujita Y, Iwata S, Nakano K, et al. A case of simultaneous onset of highly active systemic lupus erythematosus and IgG4-related renal disease. Mod Rheumatol Case Rep 6: 178-182, 2022.","DOI":"10.1093\/mrcr\/rxac002"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Gunathilake K, Rifath M, Munasinghe BM, Muhunthiny P, Vincent G. Systemic lupus erythematosus mimicking idiopathic multicentric Castleman disease: A diagnostic dilemma. SAGE Open Med Case Rep 10: 2050313X221106110, 2022.","DOI":"10.1177\/2050313X221106110"},{"key":"14","unstructured":"14. Aringer M, Costenbader K, Daikh D, et al. 2019 European League Against Rheumatism\/American College of Rheumatology classification criteria for systemic lupus erythematosus. Arthritis Rheumatol 71: 1400-1412, 2019."},{"key":"15","unstructured":"15. Mu\u00f1oz C, Isenberg DA. Review of major endocrine abnormalities in patients with systemic lupus erythematosus. Clin Exp Rheumatol 37: 791-796, 2019."},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Isenberg DA, Manson JJ, Ehrenstein MR, Rahman A. Fifty years of anti-ds DNA antibodies: are we approaching journey's end? Rheumatology (Oxford) 46: 1052-1056, 2007.","DOI":"10.1093\/rheumatology\/kem112"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Moroni G, Radice A, Giammarresi G, et al. Are laboratory tests useful for monitoring the activity of lupus nephritis? A 6-year prospective study in a cohort of 228 patients with lupus nephritis. Ann Rheum Dis 68: 234-237, 2009.","DOI":"10.1136\/ard.2008.094508"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. El Karoui K, Vuiblet V, Dion D, et al. Renal involvement in Castleman disease. Nephrol Dial Transplant 26: 599-609, 2011.","DOI":"10.1093\/ndt\/gfq427"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Yoshita K, Kawano M, Mizushima I, et al. Light-microscopic characteristics of IgG4-related tubulointerstitial nephritis: distinction from non-IgG4-related tubulointerstitial nephritis. Nephrol Dial Transplant 27: 2755-2761, 2012.","DOI":"10.1093\/ndt\/gfr761"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Lame D, Pianelli M, Morsia E, Olivieri A, Poloni A. Is there a correlation between immune thrombocytopenia and immunoglobulin G4-related disease? J Hematol 13: 174-177, 2024.","DOI":"10.14740\/jh1260"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Li S, Deng C, Chen J, Li F. Mikulicz's disease with immune Thrombocytopenia: A New Immunoglobulin G4-Mediated Disorder and Literature Review. Arch Rheumatol 34: 343-347, 2018.","DOI":"10.5606\/ArchRheumatol.2019.7070"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Nishikori A, Nishimura MF, Nishimura Y, et al. Investigation of IgG4-positive cells in idiopathic multicentric Castleman disease and validation of the 2020 exclusion criteria for IgG4-related disease. Pathol Int 72: 43-52, 2022.","DOI":"10.1111\/pin.13185"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Gonz\u00e1lez Garc\u00eda A, Fern\u00e1ndez-Mart\u00edn J, Robles Marhuenda \u00c1. Idiopathic multicentric Castleman disease and associated autoimmune and autoinflammatory conditions: practical guidance for diagnosis. Rheumatology (Oxford) 62: 1426-1435, 2023.","DOI":"10.1093\/rheumatology\/keac481"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Wallace ZS, Naden RP, Chari S, et al. The 2019 American College of Rheumatology\/European League Against Rheumatism classification criteria for IgG4-related disease. Ann Rheum Dis 79: 77-87, 2020.","DOI":"10.1136\/annrheumdis-2019-216561"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/64\/18\/64_4906-24\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T03:27:36Z","timestamp":1758338856000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/64\/18\/64_4906-24\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,15]]},"references-count":24,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.4906-24","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,15]]},"article-number":"4906-24"}}